Fennec Pharmaceuticals(FENC.US) Director Sells US$7,073.19 in Common Stock
$Fennec Pharmaceuticals(FENC.US)$ Director RALLIS CHRIS A sold 1,173 shares of common stock on Jul 5, 2024 at an average price of $6.03 for a total value of $7,073.19. Source: Announcement
Fennec Pharmaceuticals(FENC.US) Officer Sells US$14,902.03 in Common Stock
$Fennec Pharmaceuticals(FENC.US)$ Officer Raykov Rosty sold 2,431 shares of common stock on Jul 2, 2024 at an average price of $6.13 for a total value of $14,902.03.Source: Announcement What is statem
Adrian Haigh Exits as COO of Fennec Pharmaceuticals
Express News | Fennec Pharmaceuticals Inc: Adrian Haigh Has Departed From Position as COO
Express News | Fennec Pharmaceuticals Announces Management Change
Capital One Financial Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating, Maintains Target Price $17
Capital One Financial analyst Naureen Quibria maintains $Fennec Pharmaceuticals(FENC.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success
Fennec Pharmaceuticals(FENC.US) Officer Sells US$16,433.56 in Common Stock
$Fennec Pharmaceuticals(FENC.US)$ Officer Raykov Rosty sold 2,431 shares of common stock on Jun 3, 2024 at an average price of $6.76 for a total value of $16,433.56.Source: Announcement What is statem
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 26% Dip In Price Shows Sentiment Is Matching Revenues
The Fennec Pharmaceuticals Inc. (NASDAQ:FENC) share price has fared very poorly over the last month, falling by a substantial 26%. Longer-term shareholders would now have taken a real hit with the
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Fennec Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Fennec Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Express News | Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Lowers Price Target to $17
Fennec Pharmaceuticals: Temporary Setbacks With Strong Long-Term Outlook
Fennec Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Fennec Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Fennec Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 90.11% HC Wainwright & Co. $18 → $15 Maintains Buy 04/04/2024 128.14% HC Wainwright & Co. $17 →
Express News | Fennec Pharmaceuticals, Inc. : Craig-Hallum Cuts Target Price to $17 From $20
Maintained Buy Rating for Fennec Pharmaceuticals Amidst Revenue Growth and Strategic Partnerships
Express News | Fennec Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $15 From $18
Fennec Pharmaceuticals | 10-Q: Quarterly report
JAN, MTC and PROK Among Mid-day Movers
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday's session following mixed first-quarter financial results.The e-commerce giant reported fiscal fourth-quarter 2023 reven